Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179605 | 1.00 | CTSL (0.44) | CTSLCTSB | |
| SCHEMBL24755492 | 1.00 | CTSL (0.44) | CTSLCTSB | |
| SCHEMBL24754688 | 0.93 | CTSS (0.39) | CTSLCTSB | |
| SCHEMBL24754687 | 0.93 | CTSS (0.39) | CTSLCTSB | |
| SCHEMBL25561441 | 0.90 | CTSL (0.44) | CTSLCTSB | |
| SCHEMBL25559640 | 0.90 | CTSL (0.44) | CTSLCTSB | |
| SCHEMBL23824539 | 0.89 | CTSL (0.41) | CTSL | |
| SCHEMBL8278850 | 0.89 | CTSL (0.41) | CTSL | |
| SCHEMBL30248405 | 0.89 | — | — | |
| SCHEMBL24190098 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065428-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022208262-A1 | ETHER-LINKED ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | CTSL 19/4885CTSB 15/4885 |
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-12065428-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885CTSB 829/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | CTSL 19/4885CTSB 15/4885 |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | CTSL 19/4885CTSB 15/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | CTSL 19/4885CTSB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.